Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
NEUROLOGY 1997;48:38-46
© 1997 American Academy of Neurology

A Prospective, Quantitative Study of the Natural History of Facioscapulohumeral Muscular Dystrophy (FSHD)

Implications for Therapeutic Trials

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disorder localized to 4q35. Neither the gene nor the gene product has been identified. There is presently no established treatment for FSHD. Prospective data on the natural history of this disorder are essential for the effective design of therapeutic trials. We systematically followed 81 well defined FSHD patients for up to 3 years using a standardized protocol that included manual muscle testing (MMT), maximum voluntary isometric contraction testing (MVICT), and functional testing. Muscle strength was strongly associated with measures of muscle mass, age at onset, and duration of disease. Decline in strength over time was slow but detectable with both MVICT and MMT. The magnitude of decline was not associated with either age, gender, age at onset, or duration of disease. This study establishes reliable and valid measures of disease state and progression for use as outcome variables in clinical trials in FSHD, and also provides guidelines for determining sample size and duration of follow-up. A two-armed clinical trial involving 160 patients per group and 1 year of follow-up would provide 80% power to detect complete arrest of the progression of the disease. Trials with fewer patients would thus have adequate power to detect only improvements in strength, unless follow-up duration were extended well beyond 1 year.

NEUROLOGY 1997;48: 38-46

Address correspondence and reprint requests to Dr. Michael P. McDermott, Department of Biostatistics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 630, Rochester, NY 14642.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
R. M. Van den Berg-Vos, J. Visser, S. Kalmijn, K. Fischer, M. de Visser, V. de Jong, R. J. de Haan, H. Franssen, J. H. J. Wokke, and L. H. Van den Berg
A Long-term Prospective Study of the Natural Course of Sporadic Adult-Onset Lower Motor Neuron Syndromes
Arch Neurol, June 1, 2009; 66(6): 751 - 757.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
S. Pandya, W. M King, and R. Tawil
Facioscapulohumeral Dystrophy
Physical Therapy, January 1, 2008; 88(1): 105 - 113.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. H. Elsheikh, E. Bollman, M. Peruggia, W. King, G. Galloway, and J. T. Kissel
PILOT TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Neurology, April 24, 2007; 68(17): 1428 - 1429.
[Full Text] [PDF]

Home page
 NeurologyHome page
R. J. Osborne, S. Welle, S. L. Venance, C. A. Thornton, and R. Tawil
Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy
Neurology, February 20, 2007; 68(8): 569 - 577.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. J. Barohn, L. Herbelin, J. T. Kissel, W. King, A. L. McVey, D. S. Saperstein, and J. R. Mendell
Pilot trial of etanercept in the treatment of inclusion-body myositis
Neurology, January 24, 2006; 66(1_suppl_1): S123 - S124.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. M. Van den Berg-Vos, J. Visser, H. Franssen, M. de Visser, J. M. B. V. de Jong, S. Kalmijn, J. H. J. Wokke, and L. H. Van den Berg
Sporadic lower motor neuron disease with adult onset: classification of subtypes
Brain, May 1, 2003; 126(5): 1036 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis
Neurology, November 13, 2001; 57(9): 1566 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. T. Kissel, M. P. McDermott, J. R. Mendell, W. M. King, S. Pandya, R. C. Griggs, and R. Tawil
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy
Neurology, October 23, 2001; 57(8): 1434 - 1440.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. R. Rose, M. P. McDermott, C. A. Thornton, C. Palenski, W. B. Martens, and R. C. Griggs
A prospective natural history study of inclusion body myositis: Implications for clinical trials
Neurology, August 14, 2001; 57(3): 548 - 550.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. J. Felice, W. A. North, S. A. Moore, and K. D. Mathews
FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy
Neurology, May 23, 2000; 54(10): 1927 - 1931.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. R. Schwid, C. A. Thornton, S. Pandya, K. L. Manzur, M. Sanjak, M. D. Petrie, M. P. McDermott, and A. D. Goodman
Quantitative assessment of motor fatigue and strength in MS
Neurology, September 1, 1999; 53(4): 743 - 743.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. W. Orrell, R. Tawil, J. Forrester, J. T. Kissel, J. R. Mendell, and D. A. Figlewicz
Definitive molecular diagnosis of facioscapulohumeral dystrophy
Neurology, June 1, 1999; 52(9): 1822 - 1822.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by AAN Enterprises, Inc.